Fabry Disease Treatment Market

Fabry disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha galactosidase enzyme resulting in progressive organ dysfunction. This disease is caused by abnormal buildup of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, skin, kidney, gastrointestinal system, brain, heart, and central nervous system.

Fabry Disease Treatment Market contains market size and forecasts of Fabry Disease Treatment in Global, including the following market information:

Global Fabry Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Fabry Disease Treatment market was valued at 1576.6 million in 2021 and is projected to reach US$ 2243.3 million by 2028, at a CAGR of 5.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Enzyme Replacement Therapy (ERT) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Fabry Disease Treatment include Sanofi S.A., Takeda, Amicus Therapeutics Inc., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Protalix Biotherapeutics Inc., Idorsia Pharmaceuticals Ltd., Avrobio Inc. and Greenovation Biotech GmbH, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Fabry Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Fabry Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Fabry Disease Treatment Market Segment Percentages, by Type, 2021 (%)

• Enzyme Replacement Therapy (ERT)
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)
• Others

Global Fabry Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Fabry Disease Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Fabry Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Fabry Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Fabry Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Fabry Disease Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sanofi S.A.
• Takeda
• Amicus Therapeutics Inc.
• ISU Abxis Co Ltd.
• JCR Pharmaceuticals Co Ltd.
• Protalix Biotherapeutics Inc.
• Idorsia Pharmaceuticals Ltd.
• Avrobio Inc.
• Greenovation Biotech GmbH
• Moderna Therapeutics Inc.
• Green Cross Pharma Pte Ltd.